Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
Company profile
Ticker
ALBT
Exchange
Website
CEO
David K. Jin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
GLOBAL TECHNOLOGIES CORP
SEC CIK
ALBT stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Jan 23
8-K
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
11 Jan 23
8-K
Material Modifications to Rights of Security Holders
4 Jan 23
8-K
Submission of Matters to a Vote of Security Holders
30 Dec 22
8-K
Entry into a Material Definitive Agreement
14 Dec 22
DEFA14A
Additional proxy soliciting materials
12 Dec 22
DEF 14C
Information statement
25 Nov 22
DEF 14A
Definitive proxy
21 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
PRE 14C
Preliminary information
14 Nov 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.94 mm | 3.94 mm | 3.94 mm | 3.94 mm | 3.94 mm | 3.94 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 1.80 mm | 1.06 mm | 795.40 k | 565.82 k |
| Cash used (since last report) | n/a | n/a | 7.36 mm | 4.32 mm | 3.24 mm | 2.31 mm |
| Cash remaining | n/a | n/a | -3.42 mm | -384.73 k | 694.02 k | 1.63 mm |
| Runway (months of cash) | n/a | n/a | -1.9 | -0.4 | 0.9 | 2.9 |
Institutional ownership, Q3 2022
0.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 16 |
| Opened positions | 3 |
| Closed positions | 7 |
| Increased positions | 3 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 873.00 k |
| Total shares | 907.39 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 499.40 k | $320.00 k |
| Geode Capital Management | 147.62 k | $94.00 k |
| Continental Investors Services | 57.60 k | $32.00 k |
| NTRS Northern Trust | 47.28 k | $30.00 k |
| Millennium Management | 35.16 k | $23.00 k |
| Virtu Financial | 34.06 k | $22.00 k |
| BLK Blackrock | 27.97 k | $18.00 k |
| Tower Research Capital | 21.21 k | $14.00 k |
| Susquehanna International | 14.19 k | $9.00 k |
| FMR | 10.00 k | $6.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Aug 22 | Lu Wenzhao | Common Stock, $.0001 par value | Grant | Acquire A | No | No | 0.78 | 448,718 | 350.00 k | 33,192,708 |
| 25 Jul 22 | Lu Wenzhao | Common Stock, $.0001 par value | Grant | Acquire A | No | No | 0.65 | 4,442,989 | 2.89 mm | 32,742,989 |
| 25 Jul 22 | Lu Wenzhao | Common Stock, $.0001 par value | Grant | Acquire A | No | No | 0.65 | 4,443,990 | 2.89 mm | 32,743,990 |
| 18 Jul 22 | Lu Wenzhao | Common Stock, $.0001 par value | Grant | Acquire A | No | No | 0.65 | 4,440,390 | 2.89 mm | 32,740,390 |
| 21 Dec 21 | Lu Wenzhao | Common Stock, $.0001 par value | Grant | Acquire A | No | No | 1.25 | 2,400,000 | 3.00 mm | 28,300,000 |
| 21 Dec 21 | Lu Wenzhao | Common Stock, $.0001 par value | Grant | Acquire A | No | No | 1.25 | 2,400,000 | 3.00 mm | 28,300,000 |
News
Kala Pharmaceuticals, PaxMedica, Getty And Other Short Squeeze Stocks That Could Soar
23 Jan 23
Kala Pharmaceuticals, Getty Images And This Bitcoin Stock Top Short Squeeze Leaderboard: 10 Short Squeeze Stocks To Watch
17 Jan 23
Avalon GloboCare Announces Issuance Of Key U.S. Patent For Multiple Novel QTY-Code Modified Cytokine And Chemokine Protein Receptor Molecules
17 Jan 23
Avalon GloboCare Announces Deployment Of Fusion Gene Map Technology
3 Jan 23
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
29 Dec 22
Press releases
With Multiple Shots On Revenue-Generating Goals, Avalon GloboCare Positions For A Breakout 2023 ($ALBT)
31 Jan 23
Avalon GloboCare Strengthens IP Portfolio, Earns Breakthrough Patent For QTY-Code Technology ($ALBT)
24 Jan 23
Avalon GloboCare Scores Patent For Breakthrough QTY-Code Technology To Expedite Developing Better Cancer Treatments ($ALBT)
23 Jan 23
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
11 Jan 23
Avalon GloboCare Stock Completes $4.0 Million Private Placement Priced At A Premium To Accelerate Closing Accretive Acquisition ($ALBT)
19 Dec 22